Navigation Links
Surveyed U.S. Payers Are Significantly More Likely To Reimburse Biosimilars Developed By Multinational Manufacturers Compared With Those Developed By Regional Emerging Market Players
Date:7/22/2013

EXTON, Pa., July 22, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that U.S. payer trust in specific biosimilar manufacturers could dictate which companies will be most successful in the future biosimilar market.

The Biosimilars Advisory Service report entitled U.S. and EU Payer Perspectives finds that, when considering various types of potential biosimilar manufacturers, a greater proportion of surveyed U.S. payers place a high level of trust in large pharmaceutical companies with biologics and/or biosimilars experience compared with non-pharmaceutical companies or emerging market companies.  Not only are biosimilars that are developed by well-trusted companies significantly more likely to be reimbursed, but they are also more likely to encounter significantly fewer reimbursement restrictions than the branded agent.

Interviewed European payers believe that if biosimilars are produced to high quality standards and are approved by the European Medicines Agency, then generally their concerns associated with different types of manufacturer and country of production will be addressed. The majority of surveyed U.S. payers report that approval by the U.S. Food and Drug Administration (FDA) will be sufficient to allay some of their concerns about biosimilars. Looking at the data at the class level, a smaller proportion of payers say that FDA approval will address all of their concerns for biosimilar monoclonal antibodies and fusion proteins for chronic diseases, compared with biosimilar small recombinant proteins.

"Although the majority of surveyed U.S. payers believe that biosimilars and brands are very similar to one another with only minor, non-clinically significant differences, a large group believe that they are only somewhat similar with significant or possibly significant clinical differences," s
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
2. At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists Believe that Initiations of Pfizers Xeljanz in the Rheumatoid Arthritis Treatment Algorithm Will Occur Following at Least Two Biologic Failures
3. Don't Forget the Payer in Your Digital Strategy: What Payers Need and Want from Pharma
4. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Show Healthcare Payers Aren’t Taking Drug Prices Laying Down
5. SentoClone International AB Significantly Strengthens its Global Patent Portfolio Covering its Clinical Stage Sentinel Node-derived CD4 T-cell Cancer Therapy
6. Consumer Survey Indicates Mouth Guards Worsen TMJ Symptoms As Often As Significantly Improving Them – Holistic Technologies
7. U of T engineering breakthrough promises significantly more efficient solar cells
8. SHL to Invest 40 Million USD in 2013 to Significantly Expand Production Facilities
9. VIC Investor Network to Significantly Accelerate Technology Company Growth
10. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
11. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014   Sigma-Aldrich ... today it has entered into a new gene ... Medical School,s Vector Core. Under the partnership, Sigma-Aldrich ... technology, experimental design consultation, and dedicated gene editing ... accelerate gene editing-based research at the U-M Medical ...
(Date:9/18/2014)... Artificial sweeteners, promoted as aids to weight loss and ... intolerance and metabolic disease; and they do it in ... of the gut microbiota the substantial population of ... of experiments in mice and humans, were published today ... Eran Elinav of the Weizmann Institute,s Immunology Department, who ...
(Date:9/18/2014)... 2014 Pipette.com announces brand new ... Capp, and AccuPet brand of pipettes. Micropipettes are ... or less and are a great tool for ... , The micropipette promotions were designed to offer ... products to help customers find the right solution. ...
(Date:9/17/2014)... -- The global consumption of squalene / squalane is expected ... skin-identical chemical that finds applications in various end user industries ... in other applications like high grade lubrication, and fiber coating ... players and is regionally segregated. Sophim ( France ... ( Japan ), SeaDragon Marine Oils Ltd. ( ...
Breaking Biology Technology:Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that ... 2 clinical trial using intravenous,administration of REOLYSIN(R) in ... head and neck cancers. The Principal,Investigator is Dr. ... Center,(CTRC) at The University of Texas Health Science ...
... Senior-friendly ,PlanPrescriber, Software Simplifies Medicare - For Free, ... today,announced the latest release of their PlanPrescriber tool. ... worry about whether they are,getting the most out ... MIT Professor Glen Urban, provides users with easy ...
... InNexus,Biotechnology Inc. (TSX: IXS.V; OTC Bulletin Board: IXSBF),( ... generation of monoclonal antibodies based on its Dynamic ... Chairman, to present,during the Wall Street Analyst Forum ... September 10, 2008., CEO and Chairman, Jeff ...
Cached Biology Technology:Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3On-Line Medicare Advisor Saves Seniors Time, Hassle and Money 2InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC 2
(Date:9/18/2014)... New research into the Crimean-Congo hemorrhagic fever virus (CCHFV), ... in humans similar to that caused by Ebolavirus, has ... discovery has the potential to lead to novel targets ... The research, reported in a paper published today in ... scientists at the Texas Biomedical Research Institute and their ...
(Date:9/18/2014)... foliage season that prompts millions of Americans to undertake jaunts ... possibly last a little longer within a century, according to ... in some areas of the United States as summer temperatures ... the journal Global Ecology and Biogeography . For instance, ... the state tree of New Hampshire could change color ...
(Date:9/18/2014)... across racial and ethnic groups describe losing eyesight ... day-to-day life, more so than other conditions including: ... of African-Americans, 49% of non-Hispanic whites, 43% of ... disease or ailment is the worst that could ... followed by AIDS/HIV. Hispanics and Asians ranked ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... June 17 bioMETRX, Inc. (OTC,Bulletin Board: BMRX) ... announced that the Handgun Club of America has ... showing great interest in,bioMETRX,s smartTOUCH(TM) bioVAULT 2.0 and ... the touch of a finger, and recognition,taking less ...
... related to analyses of the amphioxus ( Branchiostoma floridae ... a cephalochordate residing in shallow regions of tropical and ... lacking pairs of eyes, limbs, and ears. A ... squirts) and vertebrates, amphioxus lacks the backbone or spinal ...
... genome of a marine creature led by scientists at Scripps ... light on a key area of the tree of life. ... her colleagues from the United States, Europe and Asia, have ... a small, worm-like marine animal called amphioxus, also known ...
Cached Biology News:bioMETRX, Inc. Gun Storage Products Endorsed by the Handgun Club of America 2bioMETRX, Inc. Gun Storage Products Endorsed by the Handgun Club of America 3Genome sequence of small marine creature sheds light on vertebrate origins 2Genome sequence of small marine creature sheds light on vertebrate origins 3Worm-like marine animal providing 2Worm-like marine animal providing 3
...
...
...
... Clone/PAD: ZMD.366. Immunogen: ... internal region of human SENP1. ... human ~73 kDa SENP1. ... or DYKDDDDK)-HA-tagged-SENP1 transfected Hep2 cell ...
Biology Products: